The impact of Type 2 diabetes in Parkinson’s disease
Dilan Athauda(The Francis Crick Institute), Sonia Gandhi(The Francis Crick Institute), Nirosen Vijiaratnam(Western Health), Thomas Foltynie(National Hospital for Neurology and Neurosurgery), Gurvir S. Virdi(The Francis Crick Institute), James R. Evans(The Francis Crick Institute), Minee Liane-Choi(The Francis Crick Institute), Yoav Ben‐Shlomo(University of Bristol), Donald G. Grosset(University of Glasgow), Christine Girges(National Hospital for Neurology and Neurosurgery), Anna I. Wernick(The Francis Crick Institute), Huw R. Morris(University College London), Khalida Ismail(Diabetes UK), Michael Lawton(University of Bristol)
Cited by 3
Related Papers
Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria
|Movement Disorders|2017|2.3k
World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions
|The Lancet Global Health|2019|1.2k
The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort
|Brain|2009|962
Mechanism of Oxidative Stress in Neurodegeneration
|Oxidative Medicine and Cellular Longevity|2012|940
The epidemiology of Parkinson's disease
|The Lancet|2024|809